Viatris Inc (VTRS) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds adding and 1 fund trimming or exiting versus the previous quarter. Latest close $20.28 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Davis Advisors · Rubric Capital Management · Deerfield Management — 5 tracked funds hold VTRS. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Davis Advisors | 5.13% | 75,232,254 | TRIMMED (-3.8%) Q3 filed Nov 10 |
| Rubric Capital Management | 4.98% | 34,168,743 | ADDED (+2.0%) Q3 filed Nov 16 |
| Deerfield Management | 3.35% | 20,206,170 | HELD Q3 filed Nov 16 |
| Miller Value Partners | 2.75% | 733,164 | ADDED (+0.2%) Q3 filed Nov 16 |
| Greenlight Capital | 1.13% | 2,773,470 | ADDED (+52.6%) Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +26.4% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 1,026 of 8,857 filers |
| Long-only filers among them | 1,019 |
| Change vs 2026 Q1 | +22 net · 903 entered · 881 exited |
| Shares reported, all filers | 1,042,250,664 |
| Reported value, all filers | $15.2B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $14.3B |
| Net income · FY2025 | $-3.5B |
| Total assets · FY2025 | $37.2B |
| Shares outstanding | 1,148,590,864 |
| Market cap (at latest close) | $23.3B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.
| Shares short · Oct 15, 2026 | 37,926,100 |
| Share of shares outstanding | 3.30% |
| Days to cover | 4.57 |
Shares short at recent settlements — Jul 31, 2026: 45.7M · Aug 14, 2026: 37.0M · Aug 31, 2026: 38.6M · Sep 15, 2026: 40.8M · Sep 30, 2026: 42.0M · Oct 15, 2026: 37.9M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 1K · Sep 15, 2026: 0 · Sep 30, 2026: 670 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | Paul Campbell | Officer | 50,076 | $809.7K | Jun 25, 2026 | SEC filing |
| Mar 23, 2026 | Paul Campbell | Officer | 21,350 | $283.5K | Mar 23, 2026 | SEC filing |
| Sep 11, 2025 | Le Goff Corinne | Officer | 7,032 | $72.0K | Sep 11, 2025 | SEC filing |
| Nov 12, 2024 | Campbell Paul | Officer | 26,925 | $346.7K | Nov 11, 2024 | SEC filing |
| Aug 20, 2024 | Malik Rajiv | Director | 600,000 | $7.1M | Aug 20, 2024 | SEC filing |
| Jun 13, 2024 | Malik Rajiv | Affiliate | 350,000 | $3.7M | Jun 13, 2024 | SEC filing |
| May 28, 2024 | Roman Brian | Officer | 89,419 | $928.4K | May 28, 2024 | SEC filing |
| Mar 11, 2024 | Mauro Anthony | Officer | 250,000 | $3.1M | Mar 11, 2024 | SEC filing |
| Mar 5, 2024 | Campbell Paul | Officer | 24,353 | $300.3K | Mar 5, 2024 | SEC filing |
| Mar 5, 2024 | Lyons Dillon JoEllen | Director | 20,000 | $247.2K | Mar 5, 2024 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | FMR LLC | SC 13G/A | 126,764,446.45 | 11.0% | Aug 31, 2026 | SEC filing |
| Aug 12, 2026 | DAVIS SELECTED ADVISERS | SC 13G/A | 75,232,254 | 6.5% | Jun 30, 2026 | SEC filing |
| Aug 6, 2026 | FMR LLC | SC 13G | 96,362,102.65 | 8.3% | Jun 30, 2026 | SEC filing |
| May 5, 2026 | DAVIS SELECTED ADVISERS | SC 13G/A | 78,211,191 | 6.8% | Mar 31, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 84,807,083 | 7.4% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 4, 2026 | DAVIS SELECTED ADVISERS | SC 13G/A | 78,177,984 | 6.1% | Dec 31, 2025 | SEC filing |
| Nov 10, 2025 | DAVIS SELECTED ADVISERS | SC 13G/A | 69,345,645 | 6.7% | Sep 30, 2025 | SEC filing |
| Oct 17, 2025 | BlackRock, Inc. | SC 13G/A | 76,382,158 | 6.6% | Sep 30, 2025 | SEC filing |
| Aug 11, 2025 | STATE STREET CORPORATION | SC 13G | 55,292,535 | 4.7% | Jun 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 285 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (180), Copyright/Patent/Trademark (155), Budget/Appropriations (93).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Dividend Growth — Dividends raised for more than 10 years
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Shareholder Yield — Cash returned through dividends and buybacks
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· 52-Week High — Recently printed a new 52-week high
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Dividend Growth — Dividend per share: 0.48 · Dividend yield: 2.5% · Straight dividend years: 5 · 10-yr dividend growth: —
· Cash Flow (FCF) — Latest FCF: $1.9B · FCF yield: 8.4% · Positive FCF years: 3
· Shareholder Yield — Shareholder yield: 4.7% · of which dividends: 2.5% · of which buybacks: 2.2%
· Distress Risk (Altman Z″) — Z″-Score: 0.65 · Working capital / assets: 0.07 · Retained earnings / assets: -0.01 · EBIT / assets: -0.07 · Equity / liabilities: 0.65
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2022 Q1, ranked #23 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 1 | 0.0% | -21.9% | -0.5% | -21.4% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold VTRS — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 17, 2026 | 2.01 Completion of Acquisition or Disposition of Assets · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 5, 2026 | 2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 8, 2026 | 1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on VTRS
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.